RESUMO
Cars have a high share of global transport-related CO2 emissions. To model the market diffusion of new energy carriers and powertrains like electric vehicles, fleet turnover models are commonly used. A decisive influence factor for the substitution dynamics of such transformations is the survival rate of the national car fleet of a country. It represents the likelihood of a car reaching a certain lifespan. Due to a lack of data, current methods to estimate such survival probabilities neglect the imports and exports of used cars. Existing studies are limited to countries with a predominant market of new cars, compared to low numbers of imported and exported used cars. In this study, we resolve this marked simplification and propose a new method to estimate survival probabilities for countries with a high number of imported and exported used cars. Empirical data on the car stock, on inflows of new and used cars, and on outflows of exported and scrapped cars are gathered from 71 national statistics offices. Survival rates of the car fleets of 31 European countries are derived, for which we find a pronounced regional variability. Average lifespans of cars vary from 8.0 to 35.1 years, with a mean of 18.1 years in Western and 28.4 years in Eastern European countries, revealing the high impact of cross-border flows of cars. The study also shows that survival rate estimates can be improved significantly even in the absence of reliable data if a combination of a Weibull and a Gaussian distribution is used. It is likely that the predictive power of existing models (regarding the future environmental impact of car fleets) could be improved significantly if these findings were considered accordingly. The findings of this study can directly be included in fleet turnover and policy assessment models. They also enable the analysis of economic and environmental spillover effects from the imports and exports of used cars between countries. Supplementary Information: The online version contains supplementary material available at (10.1186/s12544-020-00464-0).
RESUMO
MedCo is the first operational system that makes sensitive medical-data available for research in a simple, privacy-conscious and secure way. It enables a consortium of clinical sites to collectively protect their data and to securely share them with investigators, without single points of failure. In this short paper, we report on our ongoing effort for the operational deployment of MedCo within the context of the Swiss Personalized Health Network (SPHN) for the Swiss Molecular Tumor Board.
Assuntos
Neoplasias , Privacidade , Segurança Computacional , Confidencialidade , Registros Eletrônicos de Saúde , Humanos , Poder Psicológico , SuíçaRESUMO
Re-use of patients' health records can provide tremendous benefits for clinical research. Yet, when researchers need to access sensitive/identifying data, such as genomic data, in order to compile cohorts of well-characterized patients for specific studies, privacy and security concerns represent major obstacles that make such a procedure extremely difficult if not impossible. In this paper, we address the challenge of designing and deploying in a real operational setting an efficient privacy-preserving explorer for genetic cohorts. Our solution is built on top of the i2b2 (Informatics for Integrating Biology and the Bedside) framework and leverages cutting-edge privacy-enhancing technologies such as homomorphic encryption and differential privacy. Solutions involving homomorphic encryption are often believed to be costly and immature for use in operational environments. Here, we show that, for specific applications, homomorphic encryption is actually a very efficient enabler. Indeed, our solution outperforms prior work by enabling a researcher to securely compute simple statistics on more than 3,000 encrypted genetic variants simultaneously for a cohort of 5,000 individuals in less than 5 seconds with commodity hardware. To the best of our knowledge, our privacy-preserving solution is the first to also be successfully deployed and tested in a operation setting (Lausanne University Hospital).